Vemurafenib joins other
multi-targeted kinase inhibitors (MKIs)(sorafenib, lenvatinib) shown to be effective in this patient population; in spite of responses to these drugs, the responses are temporary and additional treatment options are needed.
Not exact matches
The study tested a lower dose of the oral
multi-targeted tyrosine
kinase inhibitor sunitinib than in previous trials, where toxicity proved too much of a problem.